Title:Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease
Volume: 24
Issue: 38
Author(s): Krasiński Zbigniew*, Stępak Hubert, Jawień Andrzej and Stanisic Michal
Affiliation:
- Department of Vascular and Endovascular Surgery, Angiology and Phlebology Poznan University of Medical Sciences, Ponzon,Poland
Keywords:
Anticoagulants, chronic kidney disease, direct oral anticoagulants, vitamin K antagonists, pharmacologic properties, dialysis.
Abstract: In daily practice, chemical substances called “direct oral anticoagulants” or DOACs are more convenient
to administer when set beside vitamin K antagonists (VKA) due to improved pharmacologic properties, fewer
drug interactions and rapid onset of action. The objective of this review was to assess whether DOACs are the
alternative for VKA in subjects with mild-to-moderate chronic kidney disease (CKD). An analysis of current
DOAC trials and studies was performed focusing on subjects with CKD. This review concludes that although
DOACS are not recommended in the course of advanced chronic kidney disease (CrCl<30mL/min) or during
dialysis, DOACS are a reasonable choice for individuals with mild to moderate CKD.
